Avalo Therapeutics Reports 2025 Financial Results and Business Updates
Avalo Therapeutics Reports 2025 Financial Results and Provides Key Business Updates
Key Highlights
- Phase 2 LOTUS Trial Topline Data Expected Q2 2026: Avalo Therapeutics (Nasdaq: AVTX) is anticipating the release of topline data from its pivotal Phase 2 LOTUS trial evaluating abdakibart (AVTX-009) for hidradenitis suppurativa (HS) in the second quarter of 2026. This marks a potentially transformational milestone for the company.
- Financial Strength and Runway: As of December 31, 2025, Avalo reported cash, cash equivalents, and short-term investments of approximately \$98.3 million, expected to fund operations into 2028. This strong cash position provides confidence in the company’s ability to reach key clinical milestones without imminent dilution risk.
- Focused R&D Investment: Research and development expenses rose significantly to \$50.1 million, up \$25.6 million from 2024, primarily due to increased costs associated with the Phase 2 LOTUS trial.
- Increased General and Administrative (G&A) Expenses: G&A expenses increased by \$5.7 million to \$22.9 million, reflecting higher stock-based compensation and expanded headcount as the company advances clinical programs.
- Net Loss and Shares Outstanding: Net loss for 2025 was \$78.3 million, compared to \$35.1 million for 2024. The increase was mainly driven by higher operating expenses and changes in other income/expense related to warrant activities in 2024. Weighted average shares outstanding (basic) increased to 13.4 million, reflecting prior financing activity and warrant exercises.
Detailed Financial Review
- Operating Expenses: Total operating expenses for 2025 were \$73.0 million, up from \$69.0 million in 2024. The increase was driven by higher R&D and G&A expenses, partly offset by a \$27.6 million in-process R&D charge in 2024 not repeated in 2025.
- Other Income/Expense Volatility: The 2024 period was impacted by significant non-cash items including a \$79.3 million excess of initial warrant fair value over private placement proceeds, a \$121.6 million change in fair value of warrant liability, and \$9.2 million in transaction costs. These items did not repeat in 2025, but a \$9.5 million expense related to derivative liabilities occurred in 2025.
- Balance Sheet:
- Cash and cash equivalents: \$15.9 million
- Short-term investments: \$82.5 million
- Total assets: \$116.5 million
- Total liabilities: \$33.4 million (including \$18.0 million non-current derivative liability)
- Total stockholders’ equity: \$83.0 million
- Per-Share Results: Basic and diluted net loss per share was \$5.84 for 2025, compared to a basic net loss per share of \$7.94 and diluted net loss per share of \$20.91 in 2024, reflecting both the higher share count and the change in non-cash items affecting earnings.
Clinical and Pipeline Updates
- LOTUS Phase 2 Trial Details:
- Approximately 250 adults with moderate to severe HS are enrolled.
- Randomized (1:1:1) to one of two abdakibart dosing regimens (bi-weekly or monthly) or placebo for a 16-week treatment phase.
- Primary endpoint: Percentage of patients achieving HiSCR75 (75% reduction in disease activity) at Week 16.
- Key secondary endpoints include HiSCR50, HiSCR90, change in International HS Severity Score System (IHS4), draining fistula count, abscess and inflammatory nodule count, and ≥30% reduction in patient-reported skin pain.
- Topline data release expected in Q2 2026—this is a major catalyst that could significantly affect share value depending on results.
- Abdakibart (AVTX-009) Mechanism: Abdakibart is a humanized monoclonal antibody targeting interleukin-1β (IL-1β), a central driver of inflammation in autoimmune and inflammatory diseases. IL-1β inhibition has shown efficacy in a range of immune-mediated conditions, suggesting broad potential for AVTX-009.
- Indication Focus—Hidradenitis Suppurativa: HS is a chronic, progressive inflammatory skin disease with significant unmet need. Prevalence estimates range from 0.7–1.2% of the U.S. population, possibly higher, and the disease causes painful nodules, abscesses, and scarring. There is high market potential for an effective new therapy.
What Investors Should Watch
- Upcoming Data Readout: The most important near-term catalyst is the LOTUS trial topline data in Q2 2026. Positive results could validate the company’s IL-1β strategy, de-risk the asset, and drive significant share appreciation. Conversely, weak or negative results could lead to a sharp decline in share price.
- Cash Position and Dilution Risk: Avalo’s projected runway into 2028 reduces the risk of near-term dilution, which is a positive for shareholders. However, future financing needs may depend on trial outcomes and strategic initiatives.
- Increased R&D Spend: The substantial increase in R&D expenses reflects a focused investment in the LOTUS trial. Investors should monitor whether spending leads to successful clinical outcomes.
- Warrant and Derivative Liabilities: While all warrants from the March 2024 private placement were exercised in 2024, the company still carries \$18 million in non-current derivative liabilities, which could impact future financial results depending on share price movements.
Forward-Looking Statements and Risks
Avalo notes that forward-looking statements are subject to significant risks and uncertainties, including clinical development risks, reliance on key personnel, regulatory challenges, the ability to enroll and retain patients, economic and market risks, and other factors detailed in SEC filings. Investors should be aware that actual results may differ materially from projections and expectations.
Contact Information
Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should consult their own financial advisors and review the company’s official filings with the SEC before making any investment decisions. The accuracy of this summary is based on the company’s disclosures as of March 23, 2026, and subsequent events may alter the outlook or data herein.
View Avalo Therapeutics, Inc. Historical chart here
